{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06395753",
            "orgStudyIdInfo": {
                "id": "Debio 4228-201"
            },
            "secondaryIdInfos": [
                {
                    "id": "U1111-1298-8943",
                    "type": "OTHER",
                    "domain": "WHO Unique Trial Identifier"
                },
                {
                    "id": "2024-511038-11",
                    "type": "OTHER",
                    "domain": "EU CT Number"
                }
            ],
            "organization": {
                "fullName": "Debiopharm International SA",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Dose Finding Study of Debio 4228 in Participants With Locally Advanced/Metastatic Prostate Cancer",
            "officialTitle": "A Phase 2, Randomized, Open-Label, Dose-Finding Study of Debio 4228, an Extended-Release Formulation of Gonadotropin-Releasing Hormone Antagonist in Participants With Locally Advanced/Metastatic Prostate Cancer",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-dose-finding-study-of-debio-in-participants-with-locally-advanced-metastatic-prostate-cancer"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-06",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-03",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-04",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-04-29",
            "studyFirstSubmitQcDate": "2024-04-29",
            "studyFirstPostDateStruct": {
                "date": "2024-05-02",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-24",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-25",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Debiopharm International SA",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The primary purpose of this study is to determine the pharmacokinetics (PK) and pharmacodynamics (PD) of Debio 4228."
        },
        "conditionsModule": {
            "conditions": [
                "Prostate Cancer"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 60,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Cohort 1: Debio 4228 Dose Level 1",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive a single intramuscular (IM) administration of dose level 1 Debio 4228 on Day 1.",
                    "interventionNames": [
                        "Drug: Debio 4228"
                    ]
                },
                {
                    "label": "Cohort 2: Debio 4228 Dose Level 2",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive a single IM administration of dose level 2 Debio 4228 on Day 1.",
                    "interventionNames": [
                        "Drug: Debio 4228"
                    ]
                },
                {
                    "label": "Cohort 3",
                    "type": "EXPERIMENTAL",
                    "description": "If any alternative dose is deemed necessary based on preliminary data, participants may be enrolled in Cohort 3 to receive Debio 4228 loading dose IM, on Day 1 followed by a maintenance dose IM, 12 weeks after receiving the loading dose (Day 85).",
                    "interventionNames": [
                        "Drug: Debio 4228"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Debio 4228",
                    "description": "Administered as IM injection.",
                    "armGroupLabels": [
                        "Cohort 1: Debio 4228 Dose Level 1",
                        "Cohort 2: Debio 4228 Dose Level 2",
                        "Cohort 3"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Maximum Plasma Concentration (Cmax) of Debio 4228",
                    "timeFrame": "Cohorts 1 and 2: Predose and at multiple time points post-dose up to Day 169; Cohort 3: Predose and at multiple time points post-dose up to Day 197"
                },
                {
                    "measure": "Area Under the Concentration-time Curve of Debio 4228 Over 12 weeks (AUC84d)",
                    "timeFrame": "Cohorts 1 and 2: Predose and at multiple time points post-dose up to Day 84; Cohort 3: Predose and at multiple time points post-dose up to Day 168"
                },
                {
                    "measure": "Plasma Concentration of Debio 4228 at Week 12 (C84d)",
                    "timeFrame": "Cohorts 1 and 2: Post-dose on Day 84; Cohort 3: Post-dose on Days 84 and 168"
                },
                {
                    "measure": "Serum Concentration of Testosterone",
                    "timeFrame": "Cohorts 1 and 2: Predose and at multiple time points post-dose from Days 1 to 85; Cohort 3: Predose and at multiple time points post-dose from Days 1 to 169"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Number of Participants who Achieved and Maintained a Testosterone Castration (Testosterone Level of <50 [Nanograms per Deciliter] ng/dL and <20 ng/dL",
                    "timeFrame": "Cohorts 1, 2, and 3: Days 29 to 85"
                },
                {
                    "measure": "Number of Participants who Maintained a Testosterone Castration (Testosterone Level of <50 ng/dL and <20 ng/dL)",
                    "timeFrame": "Cohort 3: Days 29 to 169"
                },
                {
                    "measure": "Time to Achieve Testosterone Castration (Testosterone Level of <50 ng/dL and <20 ng/dL)",
                    "timeFrame": "Cohorts 1 and 2: Day 1 up to Day 85; Cohort 3: Day 1 up to Day 169"
                },
                {
                    "measure": "Number of Participants who Experience Local Reactions Categorized as Erythema, Swelling, and Induration at the Injection Site",
                    "timeFrame": "Cohorts 1 and 2: Immediately and at 2 hours post-injection on Day 1; Cohort 3: Immediately and at 2 hours post-injection on Days 1 and 85"
                },
                {
                    "measure": "Number of Participants who Experience Pain at Injection Site",
                    "timeFrame": "Cohorts 1 and 2: Immediately and at 2 hours post-injection on Day 1; Cohort 3: Immediately and at 2 hours post-injection on Days 1 and 85"
                },
                {
                    "measure": "Number of Participants With Treatment-Emergent Adverse Events (TEAEs) By Severity",
                    "timeFrame": "Cohorts 1 and 2: Up to Day 169; Cohort 3: Up to Day 197"
                },
                {
                    "measure": "Number of Participants With Related TEAEs, Serious TEAEs, Adverse Events of Special Interest (AESIs), TEAEs Leading to Treatment Delay, and/or Discontinuation, and Death",
                    "timeFrame": "Cohorts 1 and 2: Up to Day 169; Cohort 3: Up to Day 197"
                },
                {
                    "measure": "Number of Participants With Clinically Significant Abnormalities in Laboratory, Vital Signs, and Electrocardiogram (ECG) Parameters",
                    "timeFrame": "Cohorts 1 and 2: Up to Day 169; Cohort 3: Up to Day 197"
                },
                {
                    "measure": "Percent Change From Baseline in Serum Prostate-Specific Antigen (PSA) Over Time",
                    "timeFrame": "Cohorts 1 and 2: Baseline up to Day 85; Cohort 3: Baseline up to Day 169"
                },
                {
                    "measure": "Change From Baseline of Serum Luteinizing Hormone (LH) Over Time",
                    "timeFrame": "Cohorts 1 and 2: Baseline up to Day 85; Cohort 3: Baseline up to Day 169"
                },
                {
                    "measure": "Change From Baseline in Serum Follicle-Stimulating Hormone (FSH) Over Time",
                    "timeFrame": "Cohorts 1 and 2: Baseline up to Day 85; Cohort 3: Baseline up to Day 169"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Participant with histologically confirmed locally advanced/metastatic prostate cancer\n2. Participant judged by the Study Investigator to be candidate for continuous androgen deprivation therapy (ADT)\n3. Baseline morning serum testosterone levels \\>150 ng/dL at screening visit\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n5. Life expectancy of at least 6 months\n6. Adequate bone marrow, hepatic, and renal function at the screening visit\n\n\\[Note: Other protocol and subprotocol-defined criteria apply\\]\n\nExclusion Criteria:\n\n1. Previous ADT (neoadjuvant or adjuvant hormonal therapy) for \u22656 months duration and \\<6 months treatment-free interval before start of screening\n2. Indication for androgen deprivation combination therapy\n3. History of bilateral orchiectomy, adrenalectomy, or hypophysectomy\n4. Received chemotherapy or cryotherapy within 8 weeks prior to the start of screening for the treatment of prostate cancer\n5. Abnormal cardiovascular function or diabetes\n6. Use of exogenous testosterone within 6 months before the start of screening\n7. Major surgery within 4 weeks before the start of screening\n8. Cancer disease within the last two years except for prostate cancer and some skin cancers\n\n\\[Note: Other protocol and subprotocol-defined criteria apply\\]",
            "healthyVolunteers": false,
            "sex": "MALE",
            "genderBased": true,
            "genderDescription": "Males with locally advanced/metastatic prostate cancer.",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Debiopharm International S.A",
                    "role": "CONTACT",
                    "phone": "+41 21 321 01 11",
                    "email": "clinicaltrials@debiopharm.com"
                }
            ],
            "locations": [
                {
                    "facility": "Tower Urology,",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90048",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "Biogenix Molecular",
                    "status": "RECRUITING",
                    "city": "Miami",
                    "state": "Florida",
                    "zip": "33165",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 25.77427,
                        "lon": -80.19366
                    }
                },
                {
                    "facility": "First Urology- Jeffersonville",
                    "status": "RECRUITING",
                    "city": "Jeffersonville",
                    "state": "Indiana",
                    "zip": "47130",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.27757,
                        "lon": -85.73718
                    }
                },
                {
                    "facility": "GU Research Network/Wichita Urology Group",
                    "status": "RECRUITING",
                    "city": "Wichita",
                    "state": "Kansas",
                    "zip": "67226",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 37.69224,
                        "lon": -97.33754
                    }
                },
                {
                    "facility": "New York Cancer and Blood Specialists",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Shirley",
                    "state": "New York",
                    "zip": "11697",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.80149,
                        "lon": -72.8676
                    }
                },
                {
                    "facility": "Associated Urologists of North Carolina",
                    "status": "RECRUITING",
                    "city": "Raleigh",
                    "state": "North Carolina",
                    "zip": "27612",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.7721,
                        "lon": -78.63861
                    }
                },
                {
                    "facility": "Carolina Urologic Research Center",
                    "status": "RECRUITING",
                    "city": "Myrtle Beach",
                    "state": "South Carolina",
                    "zip": "29572",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.68906,
                        "lon": -78.88669
                    }
                },
                {
                    "facility": "Urology Clinics of North Texas",
                    "status": "RECRUITING",
                    "city": "Dallas",
                    "state": "Texas",
                    "zip": "75231",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 32.78306,
                        "lon": -96.80667
                    }
                },
                {
                    "facility": "Urology of Virginia",
                    "status": "RECRUITING",
                    "city": "Virginia Beach",
                    "state": "Virginia",
                    "zip": "23462",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.85293,
                        "lon": -75.97799
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000011471",
                    "term": "Prostatic Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000005834",
                    "term": "Genital Neoplasms, Male"
                },
                {
                    "id": "D000014565",
                    "term": "Urogenital Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000005832",
                    "term": "Genital Diseases, Male"
                },
                {
                    "id": "D000091662",
                    "term": "Genital Diseases"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000011469",
                    "term": "Prostatic Diseases"
                },
                {
                    "id": "D000052801",
                    "term": "Male Urogenital Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M14335",
                    "name": "Prostatic Neoplasms",
                    "asFound": "Prostate Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8946",
                    "name": "Genital Neoplasms, Male",
                    "relevance": "LOW"
                },
                {
                    "id": "M17315",
                    "name": "Urogenital Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M2876",
                    "name": "Genital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8944",
                    "name": "Genital Diseases, Male",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14333",
                    "name": "Prostatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27095",
                    "name": "Male Urogenital Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M9789",
                    "name": "Hormones",
                    "relevance": "LOW"
                },
                {
                    "id": "M9788",
                    "name": "Hormone Antagonists",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}